Predictive role of CYFRA 21-1 for S-1 monotherapy in non-small cell lung cancer patients.
Carcinoembryonic antigen
Cytokeratin 19 fragment
Non-small cell lung cancer
Predictive marker
S-1
Journal
Respiratory investigation
ISSN: 2212-5353
Titre abrégé: Respir Investig
Pays: Netherlands
ID NLM: 101581124
Informations de publication
Date de publication:
May 2022
May 2022
Historique:
received:
09
07
2021
revised:
05
11
2021
accepted:
23
11
2021
pubmed:
27
2
2022
medline:
27
4
2022
entrez:
26
2
2022
Statut:
ppublish
Résumé
S-1, an oral fluoropyrimidine derivative, is widely used for the treatment of several solid tumors. However, there are no predictive markers for its effectiveness. We retrospectively screened 108 patients with advanced non-small cell lung cancer (NSCLC) treated via S-1 monotherapy and investigated its relationship with cytokeratin 19 fragment (CYFRA 21-1) and CEA pretreatment levels. Sixty-one patients with high CYFRA 21-1 levels had a statistically significant shorter progression-free survival (PFS) and overall survival (OS) than 46 patients with normal levels (median PFS = 42 days vs. 70 days, respectively; p = 0.0014; median OS = 197 days vs. 316 days, respectively, p = 0.0239). Serum CYFRA 21-1 levels have predictive and prognostic roles in the management of patients with advanced NSCLC on S-1 monotherapy.
Sections du résumé
BACKGROUND
BACKGROUND
S-1, an oral fluoropyrimidine derivative, is widely used for the treatment of several solid tumors. However, there are no predictive markers for its effectiveness.
METHODS
METHODS
We retrospectively screened 108 patients with advanced non-small cell lung cancer (NSCLC) treated via S-1 monotherapy and investigated its relationship with cytokeratin 19 fragment (CYFRA 21-1) and CEA pretreatment levels.
RESULTS
RESULTS
Sixty-one patients with high CYFRA 21-1 levels had a statistically significant shorter progression-free survival (PFS) and overall survival (OS) than 46 patients with normal levels (median PFS = 42 days vs. 70 days, respectively; p = 0.0014; median OS = 197 days vs. 316 days, respectively, p = 0.0239).
CONCLUSIONS
CONCLUSIONS
Serum CYFRA 21-1 levels have predictive and prognostic roles in the management of patients with advanced NSCLC on S-1 monotherapy.
Identifiants
pubmed: 35216954
pii: S2212-5345(21)00218-5
doi: 10.1016/j.resinv.2021.11.014
pii:
doi:
Substances chimiques
Antigens, Neoplasm
0
Biomarkers, Tumor
0
Carcinoembryonic Antigen
0
Keratin-19
0
antigen CYFRA21.1
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
393-399Informations de copyright
Copyright © 2022. Published by Elsevier B.V.
Déclaration de conflit d'intérêts
Conflict of Interest The authors declare no conflicts of interest.